A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

MavAcamten Real World eVidEnce coLlaboration in HCM (MARVEL-HCM)

The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US

Inclusion Criteria:

• Age ≥ 18 years at the index date
• Prescription of mavacamten for the treatment of Obstructive hypertrophic cardiomyopathy (oHCM) with NYHA Class II or III
• ≥ 12 weeks of follow-up after prescription of mavacamten, except for the baseline data reporting

Exclusion Criteria:

• Data collection as part of a clinical trial during the study period
• Participation in a myosin inhibitor clinical trial